Report of two cases of acute cardiac adverse events in patients with colorectal carcinoma receiving oral capecitabine
Lampropoulos, S; Roditis, P; Koulouris, E; Zafiris, A; Tzimou, M; Kyratlidis, K; Pavlidis, K; Godwin, SA; Kosmas, C
| HERO ID | 4239841 |
|---|---|
| Material Type | Review |
| In Press | No |
| Year | 2017 |
| Title | Report of two cases of acute cardiac adverse events in patients with colorectal carcinoma receiving oral capecitabine |
| Authors | Lampropoulos, S; Roditis, P; Koulouris, E; Zafiris, A; Tzimou, M; Kyratlidis, K; Pavlidis, K; Godwin, SA; Kosmas, C |
| Journal | Anti-Cancer Drugs |
| Volume | 28 |
| Issue | 7 |
| Page Numbers | 801-807 |
| Abstract | Capecitabine is an oral fluoropyrimidine chemotherapeutic agent, which, after oral administration, is metabolized to its active cytotoxic compound: 5-fluorouracil (5-FU). Cardiotoxicity is a recognized side effect of 5-FU, a closely related fluorinated pyrimidine antagonist. In the present report, we report on two patients who were admitted to our department after being treated with oral capecitabine for colorectal carcinoma and developed symptoms and signs of acute myocardial infarction that resolved after appropriate treatment and monitoring. The above two cases are discussed in the context of fluoropyrimidine, 5-FU, and capecitabine-induced cardiotoxicity; in addition, a detailed literature review of relevant cases and patient series reports is presented. |
| Doi | 10.1097/CAD.0000000000000509 |
| Pmid | 28489615 |
| Is Certified Translation | No |
| Dupe Override | No |
| Is Public | Yes |
| Language Text | English |